Gee 'n kort en kritiese verduideliking van die rasionaal om fluvoksamien ('n selektiewe serotonienheropname remmer (SSRI) te gebruik in die behandeling van Covid pasiente.  Jou antwoord moet toepaslike verwysings sowel as in-teks verwysings he. 

Fluvoxamine is 'n antidepressant van die selektiewe serotonien heropname inhibeerder (SSRI) en 'n σ-1 reseptor (S1R) agonis klas. Fluvoxamine verminder die produksie van sitokiene. Daar word verneem dat dit onder andere ʼn rol kan speel in die behandeling van COVID-19 pasiënte.

In a double-blind, randomized, placebo-controlled trial involving 152 outpatients with COVID-19, patients who were treated with fluvoxamine had a significantly lower risk of clinical deterioration over 15 days of treatment than those who received a placebo (Hoertel, N., 2021).

On the basis of the Bayesian beta-binomial model, there was evidence of a benefit of fluvoxamine reducing the composite primary endpoint of hospitalisation (The Lancet Global Health, 2021).

Daar is gevind dat fluvoxamine wat onder andere aan die σ-1 reseptor (S1R) van ʼn immuunsel bind, ʼn afname van inflammatoriese sitokien produksie tot gevolg het. Daar word ook verneem dat fluvoxamine die inflammatoriese gene in makrofage en endoteelselle aansienlik kan verminder en sodoende die voorkoming van die ontwikkeling van lewensgevaarlike sitokien produksie en akute respiratoriese noodsindroom in COVID-19 kan bewerkstellig. Daarom is daar aansienlike teoriee en bewysstukke wat daartoe lei dat fluvoxamine wel vir die behandeling van COVID-19 pasiënte voordeel inhou. (Medical letter, 2021:63)

Verwysing:

Hoertel, N., 2021. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19? https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786140 Datum van toegang: 1 Des. 2021

The Lancet Global Health, 2021. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext Datum van toegang: 1 Des. 2021

Medical letter. 2021. Fluvoxamine for COVID-19? https://secure.medicalletter.org/sites/default/files/freedocs/w1623d.pdf (63:69) Datum van toegang: 1 Des. 2021